An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Xencor to Present at the Barclays Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 2:25 p.m. ET / 11:25 p.m. PT.
A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product